@LeMetier what is your price?
Truth be told, this whole pin down the share price, throw in a low ball first offer, make the shareholders sweat for a bit and then make a mildly improved second offer is so transparent, it's not only embarrassing for the parties at the centre, but it is also an insult to the intelligence of the vast majority of current shareholders.
BOD "exasperated" by the lack of SP movement from the recent announcement....! Really....!
As for the whole "they're still not generating meaningful revenue" dribble. That doesn't fly either. None of the recent agreements have ever been about generating meaningful revenue. It has always been about "the technology" and collecting evidence that it can be implemented in real world settings.
I think we can all agree that this has been successful and the fact that the company entered into a confidentiality agreement with the largest pharmaceutical company in the world around the same time as a pre-submission meeting with the FDA tells me everything I need to know.
So back to your question. How much is it worth?
Not an easy task to put a price on unlocking the true potential of telehealth and remote respiratory disease diagnosis.
All I know is that I am watching one of the biggest transformations to the way health services are delivered unfold and I'll be buggered if I'll let go of my ringside tickets for anything.
I hope all other retail shareholders are seeing what I am seeing and will do the same.
Does Resapp / BOD owe us anything?
No, not really.
Should they respect the mechanism which funded their new found success, particularly when things weren't looking overly rosey?
ABSOLUTELY!!!
Will they?
Hopefully, but it doesn't look likely from where I am sitting...
